Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 30, 2026 | Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of TJ102, an FRα × CDH6 Bispecific Dual-Payload ADC | First clinical program built on Phrontline's DLP1 branched dual-payload linker platform HANGZHOU, China and SHANGHAI, Sept. 30, 2026 /PRNewswire/ -- Phrontline Biopharma, a clinical-stage biotechnology company developing next-generatio... |
| Nov 25, 2025 | Phrontline Biopharma Raises $60M in Pre-A+ Financing | Phrontline Biopharma, a Chinese antibody–drug conjugate (ADC) company, closed a $60m Pre-A+ financing round. x Please enable JavaScript Video Player is loading.Play Video Play Unmute 1xPlayback Rate 2x1.5x1x, selected0.5x Captions captions ... |
| Phrontline Biopharma | “Phrontline Biopharma Co., Ltd.” | |
| Phrontline Biopharma | “Phrontline Biopharma” |
Reviews 0
FAQ about Phrontline Biopharma
What has the press written about Phrontline Biopharma?
Parsers VC has collected 5 articles mentioning Phrontline Biopharma, among them “Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of TJ102, an FRα × CDH6 Bispecific Dual-Payload ADC” (Sep 30, 2026) and “Phrontline Biopharma Raises $60M in Pre-A+ Financing” (Nov 25, 2025).
Is Phrontline Biopharma still active?
Yes, Phrontline Biopharma is active; its latest activity on Parsers VC dates from Oct 30, 2026.